0
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Diagnostic Techniques

      Submit here before August 31, 2024

      About Pathobiology5.0 Impact Factor I 7.7 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

      Submit here before July 31, 2024

      About Oncology Research and Treatment: 2.4 Impact Factor I 3.3 CiteScore I 0.495 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Simple Scoring System for Esophagogastric Varices Prediction in Hepatocellular Carcinoma Patients without Liver Stiffness Evaluation

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: For predicting esophagogastric varices (EGVs), the Virtual Baveno VII Consensus Workshop has proposed a combination of liver stiffness determination and platelet count measurement using a FibroScan<sup>®</sup>. However, FibroScan<sup>®</sup> is not available at all institutions. The present study aimed to develop a simple method to predict development of EGV using only general blood examination results. Materials and Methods: A total of 1,090 hepatocellular carcinoma patients were enrolled, after excluding 956 with major portal vein tumor thrombus (Vp3/Vp4) or without upper gastrointestinal endoscopy examination results available. Those with EGV (≥ grade F2) or a history of treatment for the condition were defined as positive for significant EGV, and then clinical factors were retrospectively evaluated to determine indicators of occurrence. Results: Logistic multivariate analysis showed platelet count (≤12 × 10<sup>4</sup>/μL) (odds ratio [OR] 3.79, p < 0.001), mALBI grade 2a (OR 1.52, p = 0.036), and mALBI 2b or 3 (OR 3.46, p < 0.001) as significant predictive factors. Based on the OR values, platelet count (≤12 × 10<sup>4</sup>/μL) and mALBI grade 2b/3 were each assigned 2 points and mALBI 2a was given 1 point, with the result termed recommendation for EGV screening (REGS) score. Significant EGV occurrence was noted in 2.9% (9/311) of the patients with a REGS score 0, 11.0% (13/118) with a score 1, 19.3% (53/274) with a score 2, 29.5% (39/132) with a score 3, and 38.0% (97/255) with a score 4 ( p < 0.001). Conclusion: The findings indicate that REGS score can provide useful predictive information for development of significant EGV without the need for special equipment such as a FibroScan<sup>®</sup>.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

          The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

            Most patients with hepatocellular carcinoma (HCC) have associated chronic liver disease, the severity of which is currently assessed by the Child-Pugh (C-P) grade. In this international collaboration, we identify objective measures of liver function/dysfunction that independently influence survival in patients with HCC and then combine these into a model that could be compared with the conventional C-P grade.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Transection of the oesophagus for bleeding oesophageal varices

                Bookmark

                Author and article information

                Journal
                OCL
                Oncology
                10.1159/issn.0030-2414
                Oncology
                Oncology
                S. Karger AG
                0030-2414
                1423-0232
                2024
                March 2024
                11 October 2023
                : 102
                : 4
                : 291-298
                Affiliations
                [a ]Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan
                [b ]Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan
                Author notes
                *Atsushi Hiraoka, hirage@m.ehime-u.ac.jp
                Article
                533672 Oncology 2024;102:291–298
                10.1159/000533672
                37820607
                ec29737d-7bc2-4e90-aeaf-689f4babb5f7
                © 2023 S. Karger AG, Basel
                History
                : 24 May 2023
                : 05 August 2023
                Page count
                Figures: 1, Tables: 3, Pages: 8
                Funding
                The authors did not receive support from any organization for the submitted work.
                Categories
                Clinical Study

                Medicine
                Prediction,Esophagogastric varices,Hepatocellular carcinoma,Modified albumin-bilirubin grade,Platelet

                Comments

                Comment on this article